New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MEDI;PFE;CELG;PRXL;ACOR;NPSP;ALKS;AZN;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
November 12, 2014
08:13 EDTPFE, ACORBoston Biotech to hold a conference
Subscribe for More Information
08:02 EDTPFECredit Suisse to hold a conference
Subscribe for More Information
07:35 EDTAZNAdvaxis submits IND application for ADXS-HPV Phase 1/2 study, MEDI4736
Advaxis (ADXS) announced that the company has submitted an Investigational New Drug application, or IND, to the FDA to conduct a Phase 1/2 study of ADXS-HPV alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. This follows the press release issued in July announcing the clinical trial collaboration between Advaxis and MedImmune, the global biologics research and development arm of AstraZeneca (AZN).
November 11, 2014
16:05 EDTAZNAmgen, AstraZeneca say Phase 3 brodalumab study met endpoints
Subscribe for More Information
15:43 EDTPFE, AZNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
November 10, 2014
16:08 EDTNPSPNPS Pharmaceuticals sees FY14 OpEx $185M-$195M vs. prior view of $180M-$200M
Subscribe for More Information
16:07 EDTNPSPNPS Pharmaceuticals sees FY14 revenue at low end of $100M-$110M range
Subscribe for More Information
16:06 EDTNPSPNPS Pharmaceuticals reports Q3 EPS (2c), consensus 2c
Subscribe for More Information
15:26 EDTNPSPNotable companies reporting after market close
Subscribe for More Information
07:19 EDTCELG, ALKSCredit Suisse to hold a conference
Subscribe for More Information
November 7, 2014
08:03 EDTTEVATeva to present albuterol MDPI data at ACAAI
Subscribe for More Information
08:01 EDTTEVATeva announces findings from Phase III QNASL study, says QNASL 'well tolerated'
Subscribe for More Information
05:56 EDTTEVATeva implied volatility of 22 at lower end of index mean range
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use